These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 25092883)

  • 1. International experience in controlling pharmaceutical expenditure: influencing patients and providers and regulating industry - a systematic review.
    Lee IH; Bloor K; Hewitt C; Maynard A
    J Health Serv Res Policy; 2015 Jan; 20(1):52-9. PubMed ID: 25092883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical policies: effects of financial incentives for prescribers.
    Rashidian A; Omidvari AH; Vali Y; Sturm H; Oxman AD
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD006731. PubMed ID: 26239041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceutical policies: effects of educational or regulatory policies targeting prescribers.
    Suleman F; Movik E
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31721159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Aaserud M; Dahlgren AT; Kösters JP; Oxman AD; Ramsay C; Sturm H
    Cochrane Database Syst Rev; 2006 Apr; (2):CD005979. PubMed ID: 16625648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical policies: effects of cap and co-payment on rational drug use.
    Austvoll-Dahlgren A; Aaserud M; Vist G; Ramsay C; Oxman AD; Sturm H; Kösters JP; Vernby A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD007017. PubMed ID: 18254125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical policies: effects of cap and co-payment on rational use of medicines.
    Luiza VL; Chaves LA; Silva RM; Emmerick IC; Chaves GC; Fonseca de Araújo SC; Moraes EL; Oxman AD
    Cochrane Database Syst Rev; 2015 May; 2015(5):CD007017. PubMed ID: 25966337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons from international experience in controlling pharmaceutical expenditure. I: Influencing patients.
    Freemantle N; Bloor K
    BMJ; 1996 Jun; 312(7044):1469-71. PubMed ID: 8664631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical policies: effects of financial incentives for prescribers.
    Sturm H; Austvoll-Dahlgren A; Aaserud M; Oxman AD; Ramsay C; Vernby A; Kösters JP
    Cochrane Database Syst Rev; 2007 Jul; (3):CD006731. PubMed ID: 17636851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
    Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
    Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence on the effectiveness of policies promoting price transparency - A systematic review.
    Joosse IR; Tordrup D; Glanville J; Kotas E; Mantel-Teeuwisse AK; van den Ham HA
    Health Policy; 2023 Aug; 134():104681. PubMed ID: 36372608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The drug budget silo mentality: the French case.
    Le Pen C
    Value Health; 2003; 6 Suppl 1():S10-9. PubMed ID: 12846922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spending on medicines in Israel in an international context.
    Sax P
    Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of Formulary Restrictions on Patient and Payer Outcomes: A Systematic Literature Review.
    Park Y; Raza S; George A; Agrawal R; Ko J
    J Manag Care Spec Pharm; 2017 Aug; 23(8):893-901. PubMed ID: 28737993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pricing of pharmaceuticals: an international comparison.
    Dickson M
    Clin Ther; 1992; 14(4):604-10; discussion 603. PubMed ID: 1525794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promoting and supporting self-management for adults living in the community with physical chronic illness: A systematic review of the effectiveness and meaningfulness of the patient-practitioner encounter.
    Rees S; Williams A
    JBI Libr Syst Rev; 2009; 7(13):492-582. PubMed ID: 27819974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.